| Today’s Big NewsJan 9, 2024 |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now. 
|
|
| By Nick Paul Taylor Well, that was fast. Seventy seven days after Aiolos Bio launched publicly, GSK has disclosed a deal to buy the biotech and its phase 2 asthma treatment for $1 billion upfront and up to $400 million in regulatory milestones. |
|
|
|
By Max Bayer Flagship CEO Noubar Afeyan says there's more work to be done before the firm starts making deals in China, two months after opening an Asia-Pacific hub in Singapore. The company launched its first U.K.-based biotech, Quotient Therapeutics, at the end of 2023. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron,Ben Adams Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2024 in San Francisco. Yesterday Merger Monday lived up to its name with deals for Novartis, J&J and Merck, and today, we’re also starting the day with an early deal. Check out all the updates from JPM below. |
By Max Bayer Novartis’ R&D chief Fiona Marshall, Ph.D., says the company has been “pretty aggressive and active” in neuroscience-focused business development, looking for a boost to one of the company’s four key therapeutic pillars. |
By Nick Paul Taylor Blueprint Medicines is pulling back from one of its three areas of focus, dropping two non-small cell lung cancer (NSCLC) programs in response to early clinical data on the EGFR tyrosine kinase inhibitors. |
By James Waldron The center, which will be based at the headquarters of Doudna’s own Innovative Genomics Institute (IGI), will be known as the Danaher-IGI Beacon for CRISPR Cures. |
By Max Bayer TG Therapeutics has swooped in for rights to take Precision's off-the-shelf CAR-T to patients with autoimmune disease, paying $7.5 million upfront with another $2.5 million due in the next year. |
By James Waldron After Athersys made a last-ditch attempt in the fall to salvage the company in the wake of an unsatisfactory trial of an ischemic stroke cell therapy, the biotech has decided to sell all assets to Healios and file for bankruptcy. |
By Helen Floersh Prime editors delivered via a new type of virus-like particle have partially restored vision in blind mice. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer,James Waldron,Ben Adams The J.P. Morgan Healthcare Conference in San Francisco is back and here at Fierce Biotech, we’re going to bring you all the latest updates live from the life sciences event of the year. |
By Conor Hale 2023 was a banner year for Dexcom. Not only did it undertake a new major product launch, but it received the largest expansion of insurance coverage in the company’s history. And it’s got the receipts to show for it. |
By Max Bayer Computing behemoth Nvidia is expanding its march into drug development, announcing a new partnership with Amgen's deCode and adding Recursion to its AI-based discovery platform. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
